Chemical compound extends survival by months, in mice
Pancreatic cancer is especially challenging to treat – only eight percent of patients are still alive five years after diagnosis. Chemotherapy and radiation therapy are of limited benefit, and even immunotherapy – which revolutionized treatment for other kinds of cancer by activating the body’s immune system to attack cancer cells – has been largely ineffective because pancreatic tumors have ways to dampen the immune assault.
Now, researchers at Washington University School of Medicine in St. Louis and Rush University in Chicago have found a chemical compound that promotes a vigorous immune assault against the deadly cancer. Alone, the compound reduces pancreatic tumor growth and metastases in mice. But when combined with immunotherapy, the compound significantly shrank tumors and dramatically improved survival in the animals.
The findings, published July 3 in Science Translational Medicine, suggest that the immune-boosting compound could potentially make resistant pancreatic cancers susceptible to immunotherapy and improve treatment options for people with the devastating disease.
“Pancreatic cancer is a highly lethal disease, and we are in desperate need of new therapeutic approaches,” said co-senior author David DeNardo, PhD, an associate professor of medicine and of pathology and immunology at Washington University School of Medicine. “In animal studies, this small molecule led to very marked improvements and was even curative in some cases. We are hopeful that this approach could help pancreatic cancer patients.”
On paper, immunotherapies for pancreatic cancer seem like a good idea. The technique works by releasing a brake on specialized immune cells called T cells so they can attack the cancer. In the past, researchers working in the lab found they could release the brake and prod T cells into killing pancreatic cancer cells. But when doctors tried to treat people with pancreatic cancer using immunotherapies, fewer than five percent of patients improved.
This failure of immunotherapy in pancreatic cancer has puzzled scientists. But T cells aren’t the only player in the immune assault on cancer. Myeloid cells, another kind of immune cell found in and around tumors, can either tamp down or ramp up the immune response. They tilt the playing field by releasing immune molecules that affect how many T cells are recruited to the tumor, and whether the T cells show up at the tumors activated and ready to kill, or suppressed and inclined to ignore the tumor cells. In pancreatic tumors, myeloid cells typically suppress other immune cells, undermining the effects of immunotherapy.
DeNardo, co-senior author Vineet Gupta, PhD, of Rush University, and colleagues realized that releasing the brake on T cells might not be enough to treat pancreatic cancer. Unleashing the power of immunotherapy might require also shifting the balance of myeloid cells toward those that activate T cells to attack.
The researchers identified a compound, called ADH-503, that interferes with the migration of myeloid cells. Normally, pancreatic tumors are teeming with myeloid cells that suppress the immune response. When the researchers gave the compound to mice with pancreatic cancer, the number of myeloid cells in and near the tumors dropped, and the remaining myeloid cells were of the kind that promoted, rather than suppressed, immune responses. This environment translated into greater numbers of cancer-killing T cells in the tumor, significantly slower tumor growth and longer survival.
Then, the researchers – including first author Roheena Panni, MD, resident in general surgery at Washington University and Barnes-Jewish Hospital, and co-author William Hawkins, MD, the Neidorff Family and Robert C. Packman Professor of Surgery at Washington University School of Medicine – investigated whether creating this same environment could make pancreatic tumors susceptible to standard immunotherapy. First, they treated mice with a so-called PD-1 inhibitor, a standard immunotherapy used to treat other kinds of cancer. Unsurprisingly, they saw no effect. But when the researchers gave the mice the immunotherapy in conjunction with ADH-503, the tumors shrank and the mice survived significantly longer. In some experiments, all the tumors disappeared within a month of treatment, and all the mice survived for four months, when the researchers stopped monitoring them. In comparison, all the untreated mice died within six weeks.
Gupta noted that while pancreatic cancer is the third leading cause of cancer-related death in the United States, only about three percent of clinical trials for cancer immunotherapies target pancreatic cancer.
“Unlocking the promise of immunotherapies for pancreatic cancer requires a new approach,” Gupta said. “We believe these data demonstrate that targeting myeloid cells can help overcome resistance to immunotherapies.”
The strategy of boosting antitumor immune activity by shifting the balance of myeloid cells improved the effectiveness of other pancreatic cancer therapies as well, the researchers said. Mice treated with chemotherapy or radiation therapy both fared significantly better when ADH-503 was added to the regimen.
“You can’t make a one-to-one translation between animal studies and people, but this is very encouraging,” DeNardo said. “More study is needed to understand if the compound is safe and effective in people, which is why Gossamer Bio, Inc., is starting phase I safety studies in people later this year at Washington University and other sites.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- UK health service to pilot blood test that may detect 50 types of canceron November 27, 2020 at 11:26 am
The UK's National Health Service (NHS) is to pilot a simple blood test that may detect more than 50 types of cancer and, it is hoped, could help thousands of people by allowing the disease to be ...
- Blood Test That Detects 50 Types of Cancer To Be Testedon November 27, 2020 at 5:32 am
Researchers hope the Galleri blood test will be a "gamechanger" for early cancer diagnosis, potentially saving many lives.
- Pancreatic Cancer Therapeutics Diagnostics Market Growth Rate and Development Analysis to 2022on November 26, 2020 at 8:09 am
The uncontrolled growth of cells in the pancreas causes pancreatic cancer. It is an abnormal, unrestrained growth of ...
- Pancreatic cancer month - join the fight | Houghtaling and Downeyon November 24, 2020 at 3:46 am
By supporting research, staying vigilant about our own health and risk factors, and making our families and friends aware of this deadly disease, we will help drive the search for hope and a cure." ...
- U.S. pancreatic cancer deaths are expected to total 47,500 in 2020on November 23, 2020 at 6:08 pm
In 2020, deaths from pancreatic cancer in the United States are expected to total 47,500, according to the National Cancer Institute.
- November marks Pancreatic Cancer Awareness Monthon November 23, 2020 at 11:07 am
November is Pancreatic Cancer Awareness Month. Pancreatic cancer is extremely hard to detect and is the third leading cause of cancer-related deaths in the United States. Julie Fleshman, the president ...
- Pancreatic Cancer Market Research Based on COVID 19 and Analysis on Techniques and Applications Report 2020-2027on November 23, 2020 at 1:40 am
The Global Pancreatic Cancer Market is expected to exceed more than US$ 13 billion by 2024. Browse Full Report: Pancreatic cancer is origins by the unrestrained boom of cells within the pancreas.
- Alex Trebek spreads awareness about 'terrible' pancreatic cancer on pre-recorded 'Jeopardy!'on November 20, 2020 at 8:33 am
In honor of World Pancreatic Cancer Day, "Jeopardy!" aired a pre-recorded show featuring Alex Trebek's touching message about pancreatic cancer.
- The University of Verona and IntraOp® Announce PancFORT Trial for Pancreatic Canceron November 20, 2020 at 3:41 am
IntraOp Medical Corporation and the University of Verona in Italy announced today the enrollment of the first patient in the PancFORT Trial: A phase II study of primary chemotherapy, stereotactic body ...
- Pancreatic Cancer Collective Announces New PSA Campaign With Keesha Sharp To Raise Awareness About Pancreatic Cancer Clinical Trialson November 20, 2020 at 1:23 am
The Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up To Cancer (SU2C), announced today the launch of a new public service announcement (PSA) campaign, in ...
via Bing News